Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an ...

But just as it looked like Arsenal had dropped two vital points when Wolves substitute Tolu Arokodare headed a shock ...

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

The results of the lidERA trial in patients with HR-positive, HER2-negative early breast cancer – previewed last month and ...

Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive ...

Judge: 'Less than an inch and you would have faced homicide allegations.' Victim: 'Having dense bones saved my life. Being so ...

After more than 10 years, the Italian Festival is back for 2026 with plans to provide up great Italian food, music and ...

Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus ...

Customers packed a remodeled Roch’s Place in downtown St. Joseph as it reopened its doors about four months after a fire that ...